Methylphenidate increases cigarette smoking
- 280 Downloads
Methylphenidate (Ritalin) and d-amphetamine (Dexedrine), stimulants commonly prescribed for behavioral problems associated with atttention deficit hyperactivity disorder (ADHD), produce a similar constellation of behavioral effects. The results of previous studies suggest that d-amphetamine increases rates of smoking and the reinforcing effects of smoking. The effects of methylphenidate on smoking have not been assessed although it is the most commonly prescribed pharmacotherapy for ADHD and individuals with ADHD are at increased risk for smoking.
In this experiment the acute effects of a range of doses of methylphenidate (5, 10, 20, and 40 mg) and placebo were assessed in ten cigarette smokers who were not attempting to quit and were without ADHD or other Axis I psychiatric disorders.
Each dose of methylphenidate was tested once, whereas placebo was tested twice. One hour after ingesting drug, participants were allowed to smoke ad libitum for 4 h. Measures of smoking included total cigarettes smoked, total puffs, latency to the first cigarette, and carbon monoxide levels. Snacks and decaffeinated drinks were available ad libitum, and caloric intake during the 4-h smoking session was calculated.
Methylphenidate dose dependently increased the total number of cigarettes smoked, number of puffs, and carbon monoxide levels. As expected, methylphenidate dose dependently decreased the number of food items consumed and caloric intake.
The results of this experiment suggest that methylphenidate, like d-amphetamine, increases rates of cigarette smoking.
KeywordsMethylphenidate Smoking ADHD Subjective effects Humans
Attention Deficit Hyperactivity Disorder
analysis of variance
digital video disc
The authors wish to thank Frances P. Wagner, R.N., for her expert nursing assistance and Thomas E. Wooters and Angela J. Owens for their expert technical assistance. The National Institute on Drug Abuse grant DA 012665 (C.R.R.) supported this research.
- Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711CrossRefPubMedGoogle Scholar
- Center for Disease Control (CDC) (2003) Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995–1999. Morb Mort Wkly Rep 51:300–303Google Scholar
- Drug Enforcement Administration (2004) Statement by Terrance Woodworth, deputy director, office of diversion control, drug enforcement administration, before the committee on education and the workforce: subcommittee on early childhood, youth and families. http://www.dea.gov/pubs/cngrtest/ct051600.htm
- Hoffman BB (2001) Catecholamines and sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Gilman AG (eds) Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 215–268Google Scholar
- Interobserver Reliability (2004) http://www.ccny.cuny.edu/bbpsy/modules/interob_reliability.htm. Accessed 15 Jul 2004
- Lambert NM (2002) Stimulant treatment as a risk factor for nicotine use and substance abuse. In: Jensen PS, Cooper JR (eds) Attention deficit hyperactivity disorder: state of science: best practices. Civic Research Institute (CRI), Kingston, NJ, pp 18-1–18-24Google Scholar
- Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896–1901PubMedCrossRefGoogle Scholar
- National Institute on Drug Abuse (NIDA) (2002) Research report series: nicotine addiction. http://www.drugabuse.gov/researchreports/nicotine/nicotine.html
- National Survey on Drug Use and Health (NSDUH) (2002) Chapter 4: tobacco. http://www.oas.samhsa.gov/nhsda.2k2nsduh/Overview/2k2Overview.htm#chap4
- Sigmon SC, Tidey JW, Badger GJ, Higgins ST (2003) Acute effects of D-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. Psychopharmacology (Berl) 167:393–402Google Scholar
- Szatmari P (1992) The epidemiology of attention-deficit hyperactive disorder. Child Adolesc Psychiatr Clin N Am 1:361–384Google Scholar